Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR444245 (THOR-707) in head and neck squamous cell carcinoma
NCT05061420Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Oct 2021
- Primary completion
- Jul 2023
- Modality
- Cytokines & Interferons
- Countries
- 11
01
Overview
Phase 2, open-label trial of pegenzileukin in head and neck squamous cell carcinoma (HNSCC) (3 cohorts), sponsored by Sanofi. Primary endpoint: Objective Response Rate at 21 months. Started Oct 2021; status: terminated.
02
Drugs
pegenzileukin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05061420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061420.